BHCM
NGNE icon

Brevan Howard Capital Management’s Neurogene NGNE Stock Holding History

Brevan Howard Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$257K Buy
+12,754
New +$247K ﹤0.01% 1729
2025
Q4 		– Sell
-12,878
Closed -$223K – 2130
2025
Q3 		$223K Buy
+12,878
New +$259K ﹤0.01% 1703
2024
Q2 		– Sell
-8,064
Closed -$410K – 1288
2024
Q1 		$410K Buy
+8,064
New +$269K ﹤0.01% 524

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Brevan Howard Capital Management's NGNE Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Neurogene (NGNE) in Q1 2026: 12,754 shares worth $257K. The stake represents ﹤0.01% of the portfolio and ranks #1729 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in NGNE as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in NGNE in Q1 2024 and has held it in 3 quarters since. The position peaked at $410K in Q1 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Brevan Howard Capital Management held 12,754 shares of Neurogene worth $257K as of Q1 2026.
  • Neurogene was a new Brevan Howard Capital Management position in Q1 2026.
  • Neurogene made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1729 holding.
  • Brevan Howard Capital Management first reported a position in Neurogene in Q1 2024 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's Neurogene position peaked at $410K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.